Document registry — page 27
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
Phase 1 ascending dose, phase 1 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low01 Aug 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no…
Very low26 Jul 2024 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low18 Jul 2024 -
Phase 1 ascending dose, phase 1 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low17 Jul 2024 -
Single-arm open-label study of Semax in cognition over open-label extension of the parent trial. The Institute holds no reported primary result for this record and…
Very low16 Jul 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in hfpef and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low15 Jul 2024 -
Growth-hormone-releasing hormone analogue with albumin-binding drug affinity complex. Both variants are GHRH receptor agonists that increase pulsatile growth-hormone secretion and, downstream, IGF-1. The DAC variant…
Low14 Jul 2024 -
Protocol for independent third-party verification of a supplied preparation
High12 Jul 2024 -
Single-arm open-label study of Gonadorelin in gh axis over months. Primary result: Effective when delivered by pump at a physiological pulse frequency. Non-pulsatile…
Moderate12 Jul 2024 -
Consultation on the policy governing the public register of Institute members, reviewers, correspondents and contributors: who appears, what is published about each, and…
10 Jul 2024 -
Chronic immune-mediated inflammation of the intestinal tract, or disorders of intestinal permeability including coeliac disease.
08 Jul 2024 -
Consultation on the draft monograph for IGF-1 LR3, which the assessment committee released for public comment before ratification. The draft grades the compound's…
07 Jul 2024 -
Consultation on the draft monograph for LL-37, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
05 Jul 2024 -
GLP-1 receptor agonist, oral formulation with absorption enhancer. Receptor pharmacology is identical to subcutaneous semaglutide. The distinguishing pharmacology is absorption: SNAC buffers the gastric…
High28 Jun 2024 -
Consultation on the draft of CEI-MS-15, which specifies the performance a determination must achieve for documentation and states what the resulting figure does not…
27 Jun 2024 -
Randomised crossover, phase 1 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low26 Jun 2024 -
Consultation on the draft of CEI-MS-03, which specifies the performance a determination must achieve for content and states what the resulting figure does not establish…
24 Jun 2024 -
Record of documents ratified in the 2024 Q2 assessment cycle.
22 Jun 2024 -
Consultation on the draft monograph for Petrelintide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
20 Jun 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low20 Jun 2024 -
Consultation on the draft of this intervention review, which registers the question: Does the cardiovascular effect of a glucagon-like peptide-1 receptor agonist…
19 Jun 2024 -
Recombinant insulin-like growth factor 1 analogue. IGF-1 receptor agonism with greatly reduced binding-protein sequestration. The consequence is a sustained, unbuffered IGF-1 receptor signal. Because…
Very low18 Jun 2024 -
Phase 1 ascending dose, phase 1 study of Petrelintide in obesity over 16 weeks. Primary result: Weight reduction of approximately 8.6 % at 16 weeks in a phase 1b setting.
Low15 Jun 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Maridebart cafraglutide in type 2 diabetes over 52 weeks. Primary result: A smaller weight effect than in…
Low08 Jun 2024 -
Randomised, double-blind, placebo-controlled study of Epithalon in ageing over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low01 Jun 2024 -
Phase 1 ascending dose, phase 1 study of Amycretin in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low30 May 2024 -
Randomised, double-blind, active-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over 52 weeks. Primary result: A modest effect relative to interferon…
Moderate22 May 2024 -
Observational, phase 1 study of Ipamorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and publishes…
Very low21 May 2024 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes and cardiovascular over as stated in the parent protocol. The Institute holds no reported primary…
Very low20 May 2024 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low20 May 2024 -
Randomised, double-blind, placebo-controlled study of Semax in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low19 May 2024 -
Randomised withdrawal, phase 3 study of Tirzepatide in obesity randomising 670 participants over 52 weeks after a 36-week open-label lead-in. Primary result: Continued…
High18 May 2024 -
Randomised, open-label, active-controlled, phase 3 study of Liraglutide in type 2 diabetes randomising 464 participants over 26 weeks. Primary result: Difference −0.33…
High18 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low17 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low16 May 2024 -
Phase 1 ascending dose, phase 1 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low15 May 2024 -
Phase 1 ascending dose, phase 1 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary…
Very low14 May 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Tesamorelin in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low13 May 2024 -
Phase 1 ascending dose, phase 1 study of Mazdutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low12 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low12 May 2024
page 27 of 41